|Day Low/High||56.31 / 58.53|
|52 Wk Low/High||41.06 / 96.59|
Investors in Spark Therapeutics Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONCE options chain for the new August 17th contracts and identified one put and one call contract of particular interest.
In recent trading, shares of Spark Therapeutics Inc have crossed above the average analyst 12-month target price of $78.22, changing hands for $78.53/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
U.S. Food and Drug Administration (FDA) grants breakthrough therapy designation to SPK-8011 for hemophilia A
The most recent short interest data has been released for the 12/29/2017 settlement date, which shows a 1,115,785 share increase in total short interest for Spark Therapeutics Inc , to 4,833,489, an increase of 30.01% since 12/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Here are how some of the conference presenters are performing on the market Wednesday
The most recent short interest data has been released for the 11/30/2017 settlement date, which shows a 350,261 share increase in total short interest for Spark Therapeutics Inc , to 3,237,358, an increase of 12.13% since 11/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Bluebird Bio stock is flying higher by 20% Monday, following an update of its promising cancer treatments, Jim Cramer said.
Blueprint unveiled new data from its ongoing Phase 1 study of avapritinib in advanced systemic mastocytosis at the 59th American Society of Hematology Annual Meeting.
Preliminary data as of Dec. 6, 2017, show a 100-percent reduction in annualized bleeding rate (ABR) and 98-percent reduction in annualized infusion rate (AIR) in first four participants
Annualized bleeding rate (ABR) among 10 participants was reduced 97 percent following SPK-9001 administration, while factor IX concentrate use collectively was reduced 99 percent by 1.95 million international units (IU) during the 492-week cumulative follow-up period
Investor teleconference to be held Monday, Dec. 11, at 12:30 p.m.ET
Data show mean improvement demonstrated at one year post one-time administration maintained through at least three years for original intervention cohort, and two years for crossover cohort, with observation ongoing
Spark Therapeutics to receive up to an additional $25 million per terms of amendment
Spark Therapeutics gains gene therapy advisory OK for treatment restoring some sight for patients facing eventual blindness.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.